Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 90 (6), 893-900

Immunogenetic Aspects of Primary Sclerosing Cholangitis: Implications for Therapeutic Strategies

Affiliations
  • PMID: 7771416
Review

Immunogenetic Aspects of Primary Sclerosing Cholangitis: Implications for Therapeutic Strategies

A W van Milligen de Wit et al. Am J Gastroenterol.

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by fibro-obliterative inflammation of the intra- and extrahepatic bile ducts; in 70% of cases, it is associated with inflammatory bowel disease. The disease usually runs a progressive course, ultimately leading to biliary cirrhosis, hepatic failure, and sometimes cholangiocarcinoma, with a median survival of 12 yr after diagnosis. As yet, the etiology of primary sclerosing cholangitis remains unknown, although several recent studies have implicated immunogenetic factors as important pathogenic mechanisms. Besides liver transplantation for patients with end-stage cirrhotic liver disease and endoscopic therapy for patients with dominant extrahepatic bile duct strictures, recent studies have also shown promising results of drug therapy with ursodeoxycholic acid in the treatment of PSC. The purpose of this article is to summarize our current knowledge of the immunogenetic factors in the pathogenesis of PSC and to present support for drug therapy with ursodeoxycholic acid in the treatment of PSC. The genetic and immunological factors in the pathogenesis of PSC are outlined first, followed by a rationale of drug therapy with ursodeoxycholic acid in the treatment of PSC.

Similar articles

  • The Challenges in Primary Sclerosing Cholangitis--Aetiopathogenesis, Autoimmunity, Management and Malignancy
    TJ Weismüller et al. J Hepatol 48 Suppl 1, S38-57. PMID 18304683. - Review
    Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by progressive inflammation and fibrosis of the bile ducts, resulting in biliar …
  • Primary Sclerosing Cholangitis
    HJ Rodriguez et al. Semin Gastrointest Dis 14 (4), 189-98. PMID 14719769. - Review
    Primary sclerosing cholangitis (PSC) is an idiopathic, chronic cholestatic liver disease of uncertain etiopathogenesis commonly associated with inflammatory bowel disease …
  • Primary Sclerosing Cholangitis
    LM Alba et al. Minerva Gastroenterol Dietol 48 (2), 99-113. PMID 16489301.
    Primary sclerosing cholangitis (PSC) is a chronic cholestatic syndrome of unknown etiology frequently associated with inflammatory bowel disease and characterized by diff …
  • Sclerosing Cholangitis
    GR MacFaul et al. Curr Opin Gastroenterol 22 (3), 288-93. PMID 16550044. - Review
    It is likely that a number of patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreatitis in association with primary sclerosing cholan …
  • Treatment Options for Primary Sclerosing Cholangitis
    E Sinakos et al. Expert Rev Gastroenterol Hepatol 4 (4), 473-88. PMID 20678020. - Review
    Primary sclerosing cholangitis is a cholestatic liver disease characterized by inflammation and fibrosis of intra-/extrahepatic bile ducts, leading to multifocal strictur …
See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback